<?xml version='1.0' encoding='UTF-8'?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/'><id>tag:blogger.com,1999:blog-13833301</id><updated>2008-05-05T11:04:38.699-07:00</updated><title type='text'>Age Related Macular Degeneration</title><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default?start-index=26&amp;max-results=25'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default'/><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml'/><author><name>MedRounds Publications</name></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>103</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-13833301.post-4668887958216324356</id><published>2008-04-24T13:04:00.000-07:00</published><updated>2008-04-24T13:08:37.710-07:00</updated><title type='text'>Dietary Supplements and the Brain</title><summary type='text'>A very important and interesting question is whether supplementation with vitamins or fish oil retards the process of senility which is broadly termed cognitive functioning.  Some studies have shown that reduced dietary levels of betacarotene, vitamin C, or docosahexaenoic acid (DHA, an omega-3 fish oil) are associated with more rapid a decline in cognitive function in the elderly whereas other </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/04/dietary-supplements-and-brain.html' title='Dietary Supplements and the Brain'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=4668887958216324356&amp;isPopup=true' title='1 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4668887958216324356'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4668887958216324356'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-2645008909742331629</id><published>2008-04-16T14:50:00.000-07:00</published><updated>2008-04-16T14:55:03.440-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='SAILOR Anti-VEGF'/><title type='text'>Clear Sailing</title><summary type='text'>Last March (March 1, 2007), I commented on the “Dear Dr.” letter sent from Genentech about the higher risk of stokes in patients receiving 0.5mg Lucentis® compared to those receiving 0.3mg.  This risk was found in an interim analysis of the large SAILOR trial which compared the two doses.  My general message in that blog was that we should withhold judgment until the one year results are known.

</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/04/clear-sailing.html' title='Clear Sailing'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=2645008909742331629&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2645008909742331629'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2645008909742331629'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-6460425020942046873</id><published>2008-03-26T09:45:00.000-07:00</published><updated>2008-03-26T09:47:00.821-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='PrONTO'/><title type='text'>Avastin versus Lucentis</title><summary type='text'>A recent study from Bashshur and colleagues reported on 60 patients who were treated with Avastin® and then followed for one year.  They gave their AMD patients one injection of Avastin 2.5 mg and then followed them monthly with OCTs.  The injections were repeated every month until the macula was dry on OCT.  If the OCT was dry, the authors didn’t give an injection but asked the patient to return</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/03/avastin-versus-lucentis.html' title='Avastin versus Lucentis'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=6460425020942046873&amp;isPopup=true' title='3 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/6460425020942046873'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/6460425020942046873'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7041872090568107792</id><published>2008-03-17T13:08:00.000-07:00</published><updated>2008-03-17T13:15:26.249-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='phacoemulsification'/><category scheme='http://www.blogger.com/atom/ns#' term='macular degeneration'/><title type='text'>Cataract Surgery and AMD</title><summary type='text'>In the Oct 31, 2005 blog, I stated that results from the Age-Related Eye Disease Study (AREDS) indicated that cataract surgery did not influence the course of AMD.  Despite this report, there have been other smaller studies showing a possible link between cataract surgery and worsening of AMD.  Specifically there was a concern that cataract surgery may hasten the onset of the wet form of AMD.  </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/03/cataract-surgery-and-amd.html' title='Cataract Surgery and AMD'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7041872090568107792&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7041872090568107792'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7041872090568107792'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-5542320994762425270</id><published>2008-03-04T06:38:00.000-08:00</published><updated>2008-03-26T09:48:20.849-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='statistics'/><category scheme='http://www.blogger.com/atom/ns#' term='intravitreal injections'/><title type='text'>Intravitreal Injections at The University of Iowa</title><summary type='text'>I thought it was time to update our “numbers” from the Department of Ophthalmology. The tables show the total number of injections performed at our main clinic. The decrease in numbers for November and December are mainly due to bad weather and some older patients going south for the winter.  Our retinal doctors are using more Avastin® than Lucentis®. The main reason is that Avastin seems to last</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/03/intravitreal-injections-at-university.html' title='Intravitreal Injections at The University of Iowa'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=5542320994762425270&amp;isPopup=true' title='1 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5542320994762425270'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5542320994762425270'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-8259206787783186562</id><published>2008-02-12T09:51:00.000-08:00</published><updated>2008-02-12T09:53:18.226-08:00</updated><title type='text'>Vitamin E</title><summary type='text'>A recent article in JAMA showed that low vitamin E levels in the serum were associated with a decline in physical performance in elderly patients over a three year period.  There was no association between a physical decline and the serum levels of vitamin B6, vitamin B12, folic acid, vitamin D or iron.  The study was done in the Tuscany region of Italy.  The investigators tested the subjects on </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/02/vitamin-e.html' title='Vitamin E'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=8259206787783186562&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8259206787783186562'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8259206787783186562'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-4436386687344976886</id><published>2008-01-28T15:21:00.000-08:00</published><updated>2008-01-28T15:22:53.915-08:00</updated><title type='text'>The Tell Tale Heart</title><summary type='text'>I recently received this question.  This makes now the third patient who had these symptoms after an injection of Lucentis® or Avastin®.         “I received Lucentis for the fifth time. I had three in a row and then three months later one dose. After the fifth dose I became very red and my heart was racing. I went back into the doctor's office and my blood pressure had sky rocketed. They wouldn't</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/01/tell-tale-heart.html' title='The Tell Tale Heart'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=4436386687344976886&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4436386687344976886'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4436386687344976886'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7065650017670356666</id><published>2008-01-22T10:02:00.001-08:00</published><updated>2008-01-22T10:02:42.928-08:00</updated><title type='text'>Not Responding to Treatment</title><summary type='text'>I received this question recently:

“My father is suffering from AMD he has been receiving Avastin injections every 6 weeks (about 7 treatments so far) and his doctor never says he sees much improvement and he will probably need it for the rest of his life!  Should we consider a different drug?(Lucentis for example) or another doctor?”

Here are possible answers:

1. I would have the doctor </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/01/not-responding-to-treatment.html' title='Not Responding to Treatment'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7065650017670356666&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7065650017670356666'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7065650017670356666'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7379938114515875455</id><published>2008-01-02T12:11:00.000-08:00</published><updated>2008-01-02T12:13:12.335-08:00</updated><title type='text'>Reader Question: Lucentis and risk of stroke?</title><summary type='text'>I received this question recently:

My mom is 54 years old, she had a stroke (clot blood) one year ago and started to get treatment after 1 month of the stroke.  She does not have blood pressure, cholesterol or diabetes mellitus.  The major causes according to the doctors are smoking and hormone (Estrogens) which she has taken for many years because she had no uterus  since 1994.

She is taking </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2008/01/reader-question-lucentis-and-risk-of.html' title='Reader Question: Lucentis and risk of stroke?'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7379938114515875455&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7379938114515875455'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7379938114515875455'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7846389142863332809</id><published>2007-12-04T13:33:00.000-08:00</published><updated>2007-12-04T13:40:16.063-08:00</updated><title type='text'>Video: The Latest in AMD</title><summary type='text'>I recently made a presentation about the Latest in AMD Treatment to the Triangle Club in Iowa City. You can view the presentation at www.eyerounds.org/tutorials/folk/AMD11-2007.htm (or for those who prefer to type the address in, you can use the following: http://tinyurl.com/2kycg2.

So far the video only works in Internet Explorer and Safari internet browsers. My apologies to Firefox and </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/12/video-latest-in-amd.html' title='Video: The Latest in AMD'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7846389142863332809&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7846389142863332809'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7846389142863332809'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-3348896965173964580</id><published>2007-11-30T10:17:00.000-08:00</published><updated>2007-11-30T10:19:39.401-08:00</updated><title type='text'>Anxiety and the Injection Procedure</title><summary type='text'>We received this comment about the anxiety of the injections procedure.      “And, speaking strictly to the anxiety aspect of intraocular injections (not the BP spikes) -- for the first year or so of treatments, we made sure my mother took 0.5 - 1.0 mg Ativan [lorazepam] at least an hour before treatment. Eventually, the procedure became so familiar that a tranquilizer assist is no longer needed.</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/11/anxiety-and-injection-procedure.html' title='Anxiety and the Injection Procedure'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=3348896965173964580&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/3348896965173964580'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/3348896965173964580'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-2633730619773246616</id><published>2007-11-28T06:08:00.000-08:00</published><updated>2007-11-28T06:10:05.283-08:00</updated><title type='text'>Query: Worried About Stroke</title><summary type='text'>We received the following comment:

“I have had the exact treatment and result as anonymous. I had two Visudyne - the second left a hole in my vision.  I had three Lucentis with good results for six months. Vision started to get wavy again and I had a fourth Lucentis this week. I am just 55 but worried about stroke. During injection my blood pressure shot up and my pulse was high and I turned hot</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/11/query-worried-about-stroke.html' title='Query: Worried About Stroke'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=2633730619773246616&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2633730619773246616'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2633730619773246616'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-5930011907623144913</id><published>2007-11-19T08:04:00.000-08:00</published><updated>2007-11-19T08:18:07.660-08:00</updated><title type='text'>Treatments for Dry AMD</title><summary type='text'>   I recently attended The Direct Dry AMD Meeting sponsored by Duke  University.  Ninety percent of people with AMD have the dry form and can lose vision from loss of photoreceptors and RPE.  The cells are often lost in circular patches called geographic atrophy of the RPE.  The patches usually start outside the center of the macula but then enlarge and coalesce. See eye with dry AMD below:
    </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/11/treatments-for-dry-amd.html' title='Treatments for Dry AMD'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=5930011907623144913&amp;isPopup=true' title='1 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5930011907623144913'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5930011907623144913'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-4579639463876281104</id><published>2007-11-13T13:32:00.000-08:00</published><updated>2007-11-13T13:33:57.584-08:00</updated><title type='text'>Fluorescein Angiography in Pregnancy</title><summary type='text'>I received the following question recently:  “..does anyone know if fluorescein is safe to use during pregnancy?”    The answer is that no one knows.  Sodium fluorescein is a chemical dissolved in water that is injected into an arm vein.  The photographs are taken using special filters which cause the chemical to absorb light at one wavelength and emit it at another one.  The emitted light can be</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/11/fluorescein-angiography-in-pregnancy.html' title='Fluorescein Angiography in Pregnancy'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=4579639463876281104&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4579639463876281104'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/4579639463876281104'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7285215253099867276</id><published>2007-10-30T10:46:00.000-07:00</published><updated>2007-10-30T10:50:45.411-07:00</updated><title type='text'>Academy and Retinal Specialists Meet with Genentech</title><summary type='text'>The American Academy of Ophthalmology sent me this letter yesterday. Genentech has agreed to postpone its sales embargo of Avastin until January 1, 2008.

The third point below, about “Seek advanced comment,” was necessary because Genentech sent a letter to AMD patients stating that Avastin was not approved for the treatment of AMD. I was surprised when a patient called me to ask about this </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/10/academy-and-retinal-specialists-meet.html' title='Academy and Retinal Specialists Meet with Genentech'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7285215253099867276&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7285215253099867276'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7285215253099867276'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-5914418874879254016</id><published>2007-10-22T12:49:00.000-07:00</published><updated>2007-10-22T12:51:02.918-07:00</updated><title type='text'>Angry at Genentech</title><summary type='text'>I recently received this comment:

“Dr. Folk –
I'd like to highlight your point: "Most doctors use a dosing schedule of every four weeks for Lucentis and every six weeks for Avastin. Patients like this fifty percent increase in the time between injections."

My mother has wet ARMD in both eyes. While legally blind in one eye, the second eye was only subjected to one round of PDT damage before we </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/10/angry-at-genentech.html' title='Angry at Genentech'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=5914418874879254016&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5914418874879254016'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5914418874879254016'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-6088507087826085562</id><published>2007-10-16T19:06:00.000-07:00</published><updated>2008-04-07T11:15:02.559-07:00</updated><title type='text'>Who’s to Blame for High Drug Prices?</title><summary type='text'>I received this comment today:

“Dr. Folk,I'm not following your logic about "Congress throwing a monkey wrench
into capitalism". It seems to me that this whole problem is Genetech's doing,
not that of any federal or government agency.”

Let me give you the short and unthoughtful answer first. Medicare will pay drug companies their asking price for new and unique drugs. If Apple had charged $4000</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/10/whos-to-blame-for-high-drug-prices.html' title='Who’s to Blame for High Drug Prices?'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=6088507087826085562&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/6088507087826085562'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/6088507087826085562'/><author><name>MedRounds Publications</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-8198152927032921480</id><published>2007-10-13T06:32:00.000-07:00</published><updated>2007-10-13T06:33:00.061-07:00</updated><title type='text'>Genentech Pulls the Plug on Avastin®</title><summary type='text'>On October 11th, Genentech wrote the retinal community that “Genentech will no longer allow compounding pharmacies to purchase this product from wholesale distributors.”  The product in question is Avastin®.  Susan Desmond-Hellman, the President of Product Development, stated the reason for this change was that “some” physicians were using Avastin to treat wet AMD and that “the drug had not </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/10/genentech-pulls-plug-on-avastin.html' title='Genentech Pulls the Plug on Avastin®'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=8198152927032921480&amp;isPopup=true' title='3 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8198152927032921480'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8198152927032921480'/><author><name>MedRounds Publications</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7674489783917434480</id><published>2007-09-17T06:44:00.001-07:00</published><updated>2007-09-17T06:44:57.443-07:00</updated><title type='text'>Inflammation and AMD</title><summary type='text'>There is a lot of evidence that inflammation is involved in the pathogenesis of both dry and wet AMD.  Under the microscope, inflammatory cells are consistently seen in the outer retinas of eye donors who had AMD.  The most consistent genetic change associated with AMD has been in the inflammatory complement system.  Changes that results in an overactive complement system result in an increased </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/09/inflammation-and-amd.html' title='Inflammation and AMD'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7674489783917434480&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7674489783917434480'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7674489783917434480'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-5038357062954417407</id><published>2007-08-27T12:01:00.000-07:00</published><updated>2007-08-27T12:04:37.664-07:00</updated><title type='text'>Clinical Trials for Wet AMD (August 2007)</title><summary type='text'>Sorry for the summer lull in new blogs.  I’ll try to be a more faithful correspondent.  Following is some information on some of the clinical trials.

VERITAS
This trial compared combination treatment with PDT plus pegaptanib, (Macugen, OSI/Eyetech), to that of combination treatment with PDT plus triamcinolone acetonide Kenalog, (Bristol –Meyers Squibb), in two different doses (1 and 4 mg).  </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/08/clinical-trials-for-wet-amd-august-2007.html' title='Clinical Trials for Wet AMD (August 2007)'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=5038357062954417407&amp;isPopup=true' title='3 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5038357062954417407'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/5038357062954417407'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-444417480107569134</id><published>2007-06-20T07:06:00.000-07:00</published><updated>2007-06-20T07:07:12.473-07:00</updated><title type='text'>More from the Macula Society Meeting- Reinjection Intervals for Wet AMD (June 2007)</title><summary type='text'>Dr. Mark Johnson reported on his results following 15 patients with wet AMD after a single dose of Avastin®.  He found that the fluid within or under the retina resolved in 67% of the patients by the fourth week after the injection and that it had resolved in 73% of patients by eight weeks.  There were three of the 15 patients who had continued resolution of the fluid between 4 and 8 weeks.  He </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/06/more-from-macula-society-meeting.html' title='More from the Macula Society Meeting- Reinjection Intervals for Wet AMD (June 2007)'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=444417480107569134&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/444417480107569134'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/444417480107569134'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-8278460295870509938</id><published>2007-06-13T05:46:00.001-07:00</published><updated>2007-06-13T05:46:36.047-07:00</updated><title type='text'>Update from the 30th Annual Meeting of the Macula Society</title><summary type='text'>The 30th annual meeting of the Macula Society was held May 30-June 2, 2007 in London.  The meeting was attended by experts in macular disease from around the world.  There were a number of papers updating the positive results of the various Lucentis® trials including reports from the following studies: PRONTO, ANCHOR, Extension Study 2508, HORIZON, and PIER.  The Extension Study showed that </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/06/update-from-30th-annual-meeting-of.html' title='Update from the 30th Annual Meeting of the Macula Society'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=8278460295870509938&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8278460295870509938'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/8278460295870509938'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-9087929434371612116</id><published>2007-06-03T05:05:00.000-07:00</published><updated>2007-06-03T05:15:41.335-07:00</updated><title type='text'>Video Introduction to Dr. Folk's Book - Protect Your Sight</title><summary type='text'>

[VIEW IN EXTERNAL VIDEO PLAYER]

Table of contents to all the videos: http://www.medrounds.org/protect-your-sight/videos/</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/06/video-introduction-to-dr-folks-book.html' title='Video Introduction to Dr. Folk&apos;s Book - Protect Your Sight'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=9087929434371612116&amp;isPopup=true' title='0 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/9087929434371612116'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/9087929434371612116'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-2437993091953997021</id><published>2007-04-30T14:04:00.000-07:00</published><updated>2007-04-30T14:15:57.508-07:00</updated><title type='text'>Avastin® and Hypertension</title><summary type='text'>I recently received this question:

My mother (age 76) recently had intraocular Avastin injection for wet ARMD in one eye About a week later, she had PDT followed by a steroid injection. The following day, she experienced severe HTN, requiring 2 days of hospitalization! I'm trying to find out how likely it was that the Avastin was the culprit.She did have pre-existing HTN, usually well-controlled</summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/04/avastin-and-hypertension.html' title='Avastin® and Hypertension'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=2437993091953997021&amp;isPopup=true' title='1 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2437993091953997021'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/2437993091953997021'/><author><name>FEP International</name></author></entry><entry><id>tag:blogger.com,1999:blog-13833301.post-7051752211063900588</id><published>2007-04-24T11:34:00.001-07:00</published><updated>2007-04-24T11:36:36.680-07:00</updated><title type='text'>Comment from reader re: PDT and Avastin</title><summary type='text'>I would like to share with you an email I have had from a Radiologist in Australia who has macular degeneration.

Your comments on recent blog about PDT and Avastin seem to be very much true in my experience.

My left eye was repeatedly treated with PDT and over period of about 18 months, my central vision was lost though the neovascularization stopped. When I developed macular degeneration in </summary><link rel='alternate' type='text/html' href='http://www.medrounds.org/amd/2007/04/comment-from-reader-re-pdt-and-avastin.html' title='Comment from reader re: PDT and Avastin'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=13833301&amp;postID=7051752211063900588&amp;isPopup=true' title='1 Comments'/><link rel='replies' type='application/atom+xml' href='http://www.medrounds.org/amd/atom.xml' title='Post Comments'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7051752211063900588'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/13833301/posts/default/7051752211063900588'/><author><name>FEP International</name></author></entry></feed>